缩短从儿科急诊室到达到喘患者的德克萨米他给药的时间
Andrew W Kramer1, Jessica Erlich1, Karen Yaphockun1
1From the Rady Children's Hospital.
Pediatric quality & safety
|June 13, 2024
概括
我们从59分钟缩短了儿童喘恶化的德克萨米他治疗时间,从38分钟缩短到59分钟. 这项质量改善计划改善了急诊室的患者护理.
科学领域:
- 儿科急救医学 儿科急救医学
- 提高质量 提高科学 提高质量
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘恶化经常导致儿童急诊室 (ED) 的访问.
- 及时服用口服皮质类固醇,如甲,对于管理中度至重度喘恶化至关重要.
- 早期的皮质类固醇治疗可以减少ED停留时间 (LOS) 和住院.
研究的目的:
- 为了减少从到达到德克萨美沙给药的时间,儿童患者 (≥2年) 患有严重喘恶化 (儿童喘严重性评分>6).
- 具体目标是在6个月内将这个时间从60分钟缩短到30分钟.
主要方法:
- 一个多学科团队 (医生,护士,药剂师,呼吸治疗师) 使用改善模型实施了一项质量改进项目.
- 干预措施包括护理教育,电子医疗记录优化 (剂量圆形化,订单集) 和随时可用的德克萨米他 (1mg片,药片粉碎机).
- 统计过程控制用于分析初级 (使用德甲的时间) 和二次 (ED LOS,入院率) 结果.
主要成果:
- 在研究期间 (2021年10月至2022年3月) 的平均时间从到达达达克萨梅他的平均时间从59分钟减少到38分钟.
- 尽管治疗时间缩短,但出院的喘患者的ED LOS增加.
- 患者入院率没有显著变化.
结论:
- 质量改进方法有效地减少了儿童喘恶化症中使用德克萨米他的时间.
- 该计划成功地减少了从ED到达到治疗管理的中位数时间.
- 需要进一步调查以了解出院患者ED LOS的增加.
相关概念视频
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Adrenergic Agonists: Therapeutic Uses
766
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
766
Inhaled Medications
251
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
251
Antiasthma Drugs: β2-Adrenoceptor Agonists
246
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
246
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
270
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
270
Drugs Used in Lower Respiratory Disorders: Overview
412
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
412


